15% SUMMER DISCOUNT APPLIED AUTOMATICALLY FREE USA SHIPPING OVER $100 FREE WORLDWIDE SHIPPING OVER $200
Showing all 5 results
What the word means · and which compounds here actually qualify
Racetam is a chemical term with a precise meaning and nootropic is a term with a formal definition that almost nothing satisfies. Both get used loosely. A buyer reading a listing frequently cannot tell what class a compound belongs to. This page sets out what each word originally meant, which of the five compounds in this category meet either standard, and what that leaves.
| Property | Value |
|---|---|
| What racetam names | A chemical family sharing a 2-oxo-pyrrolidine acetamide core, not a mechanism |
| Origin of the family | Piracetam, synthesised in the 1960s, from which the suffix derives |
| What nootropic originally required | Five criteria set out by Giurgea, including absence of sedation or stimulation and very low toxicity |
| Why that definition matters | It was deliberately restrictive, and most compounds marketed under the word fail at least one criterion |
| Compounds in this category | Noopept, P21 in two sizes, Cerebrolysin nasal spray, Pinealon nasal spray |
| Is Noopept a racetam | No. It is a dipeptide, frequently grouped with the family because its metabolite resembles one |
| Is Noopept a peptide | Structurally yes, being a proline-containing dipeptide ester, though it is handled as a small molecule |
| P21 status | A peptidergic compound derived from a neurotrophic factor fragment, not a racetam |
| Cerebrolysin status | A porcine brain-derived peptide and amino acid mixture with no sequence and no molecular weight |
| Pinealon status | A three-residue Khavinson bioregulator, covered in depth on the brain peptides hub |
| Compounds here meeting the strict racetam definition | None |
| Page type | Category hub, not a product page |
| Schema page type | CollectionPage |
| Cornerstone content | Yes |
| Meta robots | index, follow |
| Regulatory status | Cerebrolysin holds approved formulations in several jurisdictions outside the United States. No other compound here holds approval |
The suffix describes a chemical structure and nothing else, which is the first thing most listings get wrong.
A racetam is built on a 2-oxo-pyrrolidine acetamide core. That is a five-membered ring carrying an amide side chain, and nothing about the definition goes further than the shape.
Piracetam was the first, synthesised in the 1960s, and every later member of the family takes its name from that shared ring rather than from any shared mechanism.
The distinction matters. Compounds in the family act through demonstrably different routes: some modulate glutamatergic receptors, some influence membrane fluidity, and for several the mechanism is still unresolved after fifty years of work.
So racetam is a structural label in the same way that steroid is a structural label. It tells you the skeleton and it does not tell you what the compound does.
A listing describing a compound as a racetam has therefore made a chemical claim that can be checked against the structure, which is more than most category words in this market offer.
Where the word is applied to a compound lacking that ring, the claim is simply incorrect rather than vague.
That is the situation with the best-known compound in this category.
The practical test is simple. Draw the structure, look for the five-membered ring with its amide side chain, and the question answers itself in seconds.
No literature search required.
Noopept is listed as a racetam almost everywhere and it does not have the ring.
Structurally it is a dipeptide. Specifically it is an ethyl ester built on a glycine and proline sequence, which puts it in a different chemical class altogether.
The confusion is real rather than careless. One reported metabolite is cycloprolylglycine, a cyclic dipeptide, and its ring resembles the racetam ring closely enough that the association stuck.
Its alternative name, omberacetam, makes the problem worse by attaching the suffix directly to a compound that does not qualify for it.
None of that makes the compound less interesting. It makes the naming unreliable, which matters when a researcher is reading class-level literature and applying it.
Piracetam literature is not Noopept literature, and the two compounds differ in potency by a factor frequently quoted in the hundreds, which alone should discourage treating them as equivalent.
For verification the practical consequence is that Noopept should be assessed as a small molecule with a peptide backbone, needing both mass confirmation and structural confirmation.
A certificate treating it as a simple small molecule and reporting only a mass has not distinguished it from its own hydrolysis products.
There is a further wrinkle. Noopept is an ester, so it hydrolyses, and its hydrolysis products are chemically close to the parent.
A certificate that reports only a mass cannot tell an intact ester from a partially hydrolysed sample, because the hydrolysis product differs by a small and unremarkable amount.
Chromatography separates them cleanly. Mass alone does not.
The word was coined with a definition attached, and the definition was deliberately hard to satisfy.
Corneliu Giurgea, who synthesised piracetam, set out five criteria a compound had to meet before the term applied.
It had to support memory and learning, and to hold that support up under disruptive conditions. It had to protect the brain against physical or chemical injury.
It had to increase the efficacy of cortical control mechanisms. And critically, it had to lack the pharmacology of ordinary psychotropic compounds: no sedation, no stimulation, very low toxicity.
That last criterion is the one that excludes most of what the word is now applied to, since a great many compounds marketed as nootropics are straightforwardly stimulants.
A five-criterion term applied to compounds meeting one of them has stopped being a category. It has become a marketing word.
This page uses the word because the search demand is real. It states the definition alongside it so the gap between the term and its usage is visible rather than exploited.
None of the five compounds in this category has been assessed against all five criteria in published work. That is the honest answer to whether any of them qualifies.
The definition also carried an implicit standard for evidence. Four of the five criteria describe measurable outcomes, which means a compound can be tested against them rather than merely described as meeting them.
Almost nothing in this market has been.
Five products sit here and they come from four unrelated origins, which makes the category a grouping by intended application rather than by anything chemical.
Noopept is the dipeptide described above, the only compound here with any claim to the racetam association even though the claim does not survive inspection.
P21 is peptidergic, derived from a fragment of a neurotrophic factor. It exists because the parent protein is too large to be practical as a research article.
Cerebrolysin is not a defined molecule at all. It is a porcine brain-derived peptide and amino acid mixture, so it has no sequence, no molecular weight and no CAS number, and verifying it is a manufacturing process question rather than a structural one.
Pinealon is a three-residue Khavinson bioregulator, and the brain peptides hub covers that family and its barrier argument in depth.
One small molecule. One peptide fragment. One undefined mixture, and one short bioregulator, grouped only because all four are directed at the same organ.
That organises a shop well and a literature search badly. The two should not be confused.
A researcher working here should read the compound page rather than the category page, because the category shares an intended application and no chemistry whatsoever.
Price spread across these five is wide. The bioregulator is among the cheapest articles in the catalogue and the brain-derived mixture among the more expensive, and neither price reflects how well characterised the compound is.
Reading cost as a proxy for evidence would invert the actual position here, as it does across the neuroactive range generally.
Format varies too. Two of the five are nasal sprays, which means their degradation clock started at the fill line rather than at reconstitution.
That matters here more than it would elsewhere, because a mixture with no defined structure cannot be re-assayed by a buyer to check how far it has drifted.
Ask for the fill date.
The checks differ by compound more than in any other category on this site, because the four origins need four different approaches.
For Noopept, mass confirmation and structural confirmation both. It is an ester, it hydrolyses, and the products are chemically close to the parent.
For P21, the sequence written out in full, since it is a defined peptide and a trade name on its own carries no chemical information whatsoever.
For Cerebrolysin, the manufacturing process and batch-to-batch consistency data, because there is no structure to confirm and no mass to match.
For Pinealon, the ordinary bioregulator panel: sequence, calculated mass against observed mass, counterion identity and net peptide content.
For the nasal spray formats in this category, the fill date, since solution-state material has been degrading since manufacture.
Across all of them, purity by chromatography with the method and detection wavelength stated, and the chromatogram rather than a summary figure.
Where one generic certificate template covers compounds this different, the template is doing work that analysis should be doing.
That is visible from a single certificate and it is worth checking before an order rather than after it arrives.
None of this is expensive to ask for. It is a single email, sent before the order rather than after the material has arrived and the question has become academic.
The response time is itself informative. A supplier who holds real lot data answers within a day, because the answer is already sitting in a file somewhere rather than needing to be constructed.
Silence is an answer too.
Selected references on the original definition, on the chemical family and on two of the compounds here.
It names a chemical family sharing a 2-oxo-pyrrolidine acetamide core, a five-membered ring with an amide side chain. It describes a skeleton rather than a mechanism, in the same way that steroid does.
From piracetam, synthesised in the 1960s, which was the first member of the family. Every later member takes the suffix from that shared ring structure.
No. Compounds in the family act through demonstrably different routes. Some modulate glutamatergic receptors, some influence membrane fluidity, and for several the mechanism remains unresolved.
No. It is a dipeptide and it does not have the ring. The confusion arises because one of its reported metabolites is a cyclic dipeptide whose ring resembles the racetam ring closely enough that the association stuck.
The alternative name makes it worse, attaching the suffix directly to a compound that does not qualify.
Not directly. The two compounds are chemically distinct and differ in potency by a factor frequently quoted in the hundreds, so treating them as equivalent misapplies the source material.
Giurgea set out five criteria, including support for memory and learning, protection of the brain against injury, and critically the absence of ordinary psychotropic pharmacology, meaning no sedation, no stimulation and very low toxicity.
None of the five has been assessed against all five criteria. That is the honest answer, and it is different from saying they fail.
Because the criterion excluding sedation and stimulation rules out a great many compounds now marketed under the word. A five-criterion term applied to compounds meeting one has stopped being a category.
A peptidergic compound derived from a fragment of a neurotrophic factor, developed as a smaller and more stable stand-in for a protein too large to be practical as a research article.
It is not a defined molecule. It is a porcine brain-derived peptide and amino acid mixture with no sequence, no molecular weight and no CAS number, so verification is a manufacturing process question.
Intended application and nothing else. One small molecule, one peptide fragment, one undefined mixture and one short bioregulator, grouped because they are directed at the same organ.
Racetam and nootropic research compounds are sold exclusively for laboratory research use. They are not a drug, food, or cosmetic product, and they are not a dietary product of any kind. They are not approved by the FDA or any comparable authority for human or veterinary use, racetam names a chemical structure rather than a mechanism, the original nootropic definition sets five criteria that none of these compounds has been assessed against in full, Cerebrolysin holds approved formulations in several jurisdictions outside the United States but material supplied here is not that product, and no other compound in this category holds approval anywhere. These products are not intended to diagnose, treat, cure, or prevent any disease. They must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
